Prof David Teachey speaks to ecancer about the COG trial which was recently presented at ASH 2020.
The topic of this study was ‘Cranial radiation can be eliminated in most children with T-cell acute lymphoblastic leukaemia (T-ALL) and bortezomib potentially improves survival in children with T-cell lymphoblastic lymphoma (T-LL): results of Children’s Oncology Group (COG) Trial'.
He first gives the background of the trial and then talks about how it was carried out. Then Dr Teachey spoke of the key results saying, outcomes for SR and IR patients with T-ALL and T-LL treated with bortezomib were excellent despite the elimination of prophylactic CXRT.
Bortezomib significantly improved 3-year EFS for these groups, comprising ~95% of patients. Outcomes for VHR patients were dismal and worse on the bortezomib arm.
T-LL patients had signitrial backbone. In the end he talks about how this study can impact the future treatment of paediatric T-cell lymphoblastic lymphoma.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.